Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag
Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157/V940, in combination with Keytruda, for the adjuvant treatment of patients with high-risk melanoma after complete resection. FDA's decision was backed by data from a phase 2b trial, dubbed KEYNOTE-942/mRNA- 4157-P201.
Published 3 months ago
News Articles
More Filters
All
Left
Center
Right
Time & Location
Sources are mostly out of (0)
Bias Distribution
67% of the sources lean Right
C 33%
R 67%
See less detail
